Delivery from episcleral exoplants

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 10, 2006, Pages 4532-4539

  Pontes De Carvalho, Ricardo A ^a   Krausse, Melissa L ^a   Murphree, A Linn ^b   Schmitt, Edward E ^c   Campochiaro, Peter A ^a   Maumenee, Irene H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c 3T Ophthalmics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN SODIUM; POLYETHYLENE; SILICONE; CONTRAST MEDIUM; FLUORESCEIN; SILASTIC;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ARTICLE; CONTROLLED STUDY; EXPLANT; FLUOROPHOTOMETRY; HISTOLOGY; IMPLANTATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINA; SCLERA; VITREOUS BODY; ANIMAL; AREA UNDER THE CURVE; DRUG DELIVERY SYSTEM; DRUG IMPLANT; INJECTION; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTERIOR CHAMBER; AREA UNDER CURVE; BIOLOGICAL TRANSPORT; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; FLUORESCEIN; FLUOROPHOTOMETRY; INJECTIONS; POLYETHYLENE; RABBITS; RETINA; SCLERA; SILICONE ELASTOMERS; VITREOUS BODY;

EID: 33750600023     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0030     Document Type: Article

References (23)

1. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization. Arch Ophtalmol. 1996;114:66-71.
2. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is an important stimulator in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:3158-3164.
3. Ozaki H, Seo M-S, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 2000;156:679-707.
4. Kryzstolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
5. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
6. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113:1479-1496.
7. Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol. 1995;120:55-64.
8. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112:1916.
9. Cardillo JA, Melo LAJ, Costa RA, et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2005;112:1557-1563.
10. Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci. 2005;46:3845-3849.
11. Inoue M, Takeda K, Monta K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentration of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol. 2004;138:1046-1048.
12. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41:1181-1185.
13. Cunha-Vaz J, Faria de Abreu JR, Campos AJ. Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol. 1975;59:649-656.
14. Maurice DM, Polgar J. Diffusion across the sclera. Exp Eye Res. 1977;25:577-582.
15. Lee S-B, Geroski DH, Prausnitz MR, Edelhauser HF. Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems. Exp Eye Res. 2004;78:599-607.
16. Cruysberg LPJ, Nuijts MMA, Geroski KH, Gilbert JA, Hendrikse F, Edelhauser HF. The influence of intraocular pressure on the transscleral diffusion of high-molecular-weight compounds. Invest Ophthalmol Vis Sci. 2005;46:3790-3794.
17. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000;41:1186-1191.
18. Kim HG, Robinson MR, Lizak MJ, et al. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci. 2004;45:2722-2731.
19. Robinson MR, Lee SS, Kim H, et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res. 2006;82:479-487.
20. Gehlbach P, Demetriades AM, Yamamoto S, et al. Periocular gene transfer of sFlt-1 suppresses ocular neovascularilation and VEGF-induced breakdown of the blood-retinal barrier. Hum Gene Ther. 2003;14:129-141.
21. Gehlbach P, Demetriades AM, Yamamoto S, et al. Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Ther. 2003;10:637-646.
22. Saishin Y, Silva RL, Saishin Y, et al. Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. Hum Gene Ther. 2005;16:473-478.
23. Kato A, Kimura H, Okabe K, Okabe J, Kunou N, Ogura Y. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest Ophthalmol Vis Sci. 2004;45:238-244.